Department of Pathology, George Emil Palade University of Medicine, Pharmacy, Sciences and Technology, 38 Gheorghe Marinescu Street, 540139 Targu Mures, Romania.
Department of Pathology, Clinical County Emergency Hospital, 540139 Targu Mures, Romania.
Int J Mol Sci. 2021 Nov 3;22(21):11918. doi: 10.3390/ijms222111918.
Although skin melanoma (SKM) represents only one-quarter of newly diagnosed skin malignant tumors, it presents a high mortality rate. Hence, new prognostic and therapeutic tools need to be developed. This study focused on investigating the prognostic value of the subcellular expression of BRAF, KRAS, and KIT in SKM in correlation with their gene-encoding interactions. In silico analysis of the abovementioned gene interactions, along with their mRNA expression, was conducted, and the results were validated at the protein level using immunohistochemical (IHC) stains. For IHC expression, the encoded protein expressions were checked on 96 consecutive SKMs and 30 nevi. The UALCAN database showed no prognostic value for the mRNA expression level of KRAS and BRAF and demonstrated a longer survival for patients with low mRNA expression of KIT in SKMs. IHC examinations of SKMs confirmed the UALCAN data and showed that KIT expression was inversely correlated with ulceration, Breslow index, mitotic rate, and pT stage. KRAS expression was also found to be inversely correlated with ulceration and perineural invasion. When the subcellular expression of BRAF protein was recorded (nuclear vs. cytoplasmatic vs. mixed nucleus + cytoplasm), a direct correlation was emphasized between nuclear positivity and lymphovascular or perineural invasion. The independent prognostic value was demonstrated for mixed expression of the BRAF protein in SKM. BRAF cytoplasmic predominance, in association with KIT's IHC positivity, was more frequently observed in early-stage nonulcerated SKMs, which displayed a low mitotic rate and a late death event. The present study firstly verified the possible prognostic value of BRAF subcellular localization in SKMs. A low mRNA expression or IHC cytoplasmic positivity for KIT and BRAF might be used as a positive prognostic parameter of SKM. SKM's BRAF nuclear positivity needs to be evaluated in further studies as a possible indicator of perineural and lymphovascular invasion.
尽管皮肤黑色素瘤 (SKM) 仅占新诊断的皮肤恶性肿瘤的四分之一,但它的死亡率很高。因此,需要开发新的预后和治疗工具。本研究重点研究了 BRAF、KRAS 和 KIT 的亚细胞表达在 SKM 中的预后价值,以及它们的基因编码相互作用。对上述基因相互作用及其 mRNA 表达进行了计算机分析,并使用免疫组织化学 (IHC) 染色在蛋白质水平上验证了结果。对于 IHC 表达,在 96 例连续 SKM 和 30 例痣中检查了编码蛋白的表达。UALCAN 数据库显示 KRAS 和 BRAF mRNA 表达水平无预后价值,并表明 SKM 中 KIT mRNA 低表达的患者生存时间更长。SKM 的 UALCAN 数据证实了 IHC 检查,并表明 KIT 表达与溃疡、Breslow 指数、有丝分裂率和 pT 分期呈负相关。还发现 KRAS 表达与溃疡和神经周围浸润呈负相关。当记录 BRAF 蛋白的亚细胞表达(核 vs. 细胞质 vs. 混合核+细胞质)时,强调了核阳性与血管淋巴管或神经周围浸润之间的直接相关性。混合 BRAF 蛋白表达在 SKM 中表现出独立的预后价值。BRAF 细胞质优势,与 KIT 的 IHC 阳性相关,在非溃疡性早期 SKM 中更为常见,这些 SKM 显示出低有丝分裂率和晚期死亡事件。本研究首次验证了 BRAF 亚细胞定位在 SKM 中的可能预后价值。KIT 和 BRAF 的低 mRNA 表达或 IHC 细胞质阳性可能作为 SKM 的阳性预后参数。SKM 的 BRAF 核阳性需要在进一步的研究中进行评估,作为神经周围和血管淋巴管浸润的可能指标。